Subtopic Deep Dive

Hawthorn Herbal Medicine Clinical Efficacy
Research Guide

What is Hawthorn Herbal Medicine Clinical Efficacy?

Hawthorn herbal medicine clinical efficacy evaluates randomized controlled trials and meta-analyses of Crataegus extracts in treating NYHA class II-III heart failure, hypertension, and dyslipidemia, alongside safety profiles with standard cardiac drugs.

Over 20 clinical studies assess hawthorn monotherapy and adjunctive use in cardiovascular conditions, with standardized leaf-flower extracts predominant. Key trials like HERB CHF (Zick et al., 2009, 59 citations) tested exercise capacity improvements. Meta-analyses by Wang et al. (2013, 119 citations) and Holubarsch et al. (2017, 52 citations) synthesize evidence on symptom relief and risk reduction.

Curated Papers

Key Challenges

Why It Matters

Hawthorn extracts improve submaximal exercise capacity in NYHA II-III heart failure patients on standard therapy (Zick et al., 2009). Systematic reviews confirm blood pressure reductions in hypertension (Cloud et al., 2019), supporting adjunctive cardiology use. Benefit-risk assessments validate WS 1442 extract safety with minimal adverse events (Holubarsch et al., 2017), guiding integrative treatment protocols amid rising CVD prevalence.

Key Research Challenges

Heterogeneity in Extract Standardization

Clinical trials use varying hydroalcoholic leaf-flower extracts, complicating meta-analyses (Koch and Malek, 2011). Standardization to flavonoids and procyanidins differs across studies. This variability limits pooled efficacy estimates in heart failure trials.

Limited Long-Term Safety Data

Short-term trials dominate, with sparse data on chronic use alongside beta-blockers or ACE inhibitors (Holubarsch et al., 2017). Potential herb-drug interactions remain underexplored (Suroowan and Mahomoodally, 2015). NYHA III patients show higher dropout rates needing extended monitoring.

Small Sample Sizes in RCTs

Trials like HERB CHF enrolled under 150 patients, reducing statistical power (Zick et al., 2009). Meta-analyses aggregate heterogeneous populations for hypertension and dyslipidemia (Wang et al., 2013). Larger multicenter RCTs are needed for subgroup efficacy.

Essential Papers

Effect of<i>Crataegus</i>Usage in Cardiovascular Disease Prevention: An Evidence-Based Approach

Jie Wang, Xing-Jiang Xiong, Bo Feng · 2013 · Evidence-based Complementary and Alternative Medicine · 119 citations

Hawthorn ( Crataegus oxyacantha ) is a widely used Chinese herb for treatment of gastrointestinal ailments and heart problems and consumed as food. In North America, the role of treatment for heart...

Roles and Mechanisms of Hawthorn and Its Extracts on Atherosclerosis: A Review

Min Wu, Longtao Liu, Yanwei Xing et al. · 2020 · Frontiers in Pharmacology · 91 citations

Cardiovascular disease (CVD), especially atherosclerosis, is a leading cause of morbidity and mortality globally; it causes a considerable burden on families and caregivers and results in significa...

Standardized Extracts from Hawthorn Leaves and Flowers in the Treatment of Cardiovascular Disorders – Preclinical and Clinical Studies

E Koch, Fathi A. Malek · 2011 · Planta Medica · 64 citations

Extracts from different parts of hawthorn plants (Crataegus spp.) are used worldwide for the treatment of cardiovascular diseases. So far, almost all clinical studies have been conducted with stand...

Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) Trial

Suzanna M. Zick, Bonnie Motyka Vautaw, Brenda W. Gillespie et al. · 2009 · European Journal of Heart Failure · 59 citations

Aims Hawthorn's efficacy when added to contemporary evidence‐based heart failure therapy is unknown. We aimed to determine whether hawthorn increases submaximal exercise capacity when added to stan...

Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review

Christian Holubarsch, Wilson S. Colucci, Jaan Eha · 2017 · American Journal of Cardiovascular Drugs · 52 citations

The effect of hawthorn (Crataegus spp.) on blood pressure: A systematic review

Alexa Cloud, Dwan Vilcins, Bradley McEwen · 2019 · Advances in Integrative Medicine · 49 citations

Hawthorn Fruit Extract Elevates Expression of Nrf2/HO-1 and Improves Lipid Profiles in Ovariectomized Rats

Jeong‐Hyun Yoo, Yanan Liu, Hyun‐Sook Kim · 2016 · Nutrients · 48 citations

The purpose of this study was to investigate the effects of hawthorn (Crataegus pinnatifida Bunge) extract on the lipid profiles and antioxidant properties in ovariectomized (OVX) rats. After ovari...

Reading Guide

Foundational Papers

Start with Wang et al. (2013, 119 citations) for evidence synthesis; Koch and Malek (2011, 64 citations) for extract standardization; Zick et al. (2009, 59 citations) for primary RCT design in heart failure.

Recent Advances

Holubarsch et al. (2017, 52 citations) for benefit-risk; Cloud et al. (2019, 49 citations) for hypertension meta-review; Wu et al. (2020, 91 citations) for atherosclerosis mechanisms.

Core Methods

Hydroalcoholic leaf-flower extracts standardized to 18.75% vitexin-2-rhamnoside; endpoints include NYHA class, 6MWT, ejection fraction; analyses use ITT with ANOVA and meta-regression for heterogeneity.

How PapersFlow Helps You Research Hawthorn Herbal Medicine Clinical Efficacy

Discover & Search

Research Agent uses searchPapers with 'hawthorn Crataegus NYHA heart failure RCT' to retrieve 50+ papers including Wang et al. (2013); citationGraph maps influence from foundational Koch and Malek (2011) to recent Wu et al. (2020); findSimilarPapers expands from Zick et al. (2009) HERB CHF trial; exaSearch uncovers adjunctive therapy safety data.

Analyze & Verify

Analysis Agent applies readPaperContent to extract endpoints from Zick et al. (2009); verifyResponse with CoVe cross-checks meta-analysis claims from Holubarsch et al. (2017); runPythonAnalysis performs GRADE grading on RCTs via pandas meta-analysis of effect sizes and heterogeneity I² statistics for blood pressure trials.

Synthesize & Write

Synthesis Agent detects gaps in long-term safety data across Wang et al. (2013) and Cloud et al. (2019); flags contradictions in lipid profile outcomes; Writing Agent uses latexEditText for trial comparison tables, latexSyncCitations for 20-paper bibliography, latexCompile for full review PDF, and exportMermaid for hawthorn mechanism flowcharts.

Use Cases

"Meta-analyze hawthorn RCTs for NYHA II heart failure exercise capacity"

Research Agent → searchPapers + citationGraph → Analysis Agent → runPythonAnalysis (pandas forest plot of 10 RCTs from Zick et al. 2009) → GRADE evidence table output.

"Draft LaTeX review on hawthorn blood pressure effects with citations"

Synthesis Agent → gap detection in Cloud et al. 2019 → Writing Agent → latexEditText (intro/results) → latexSyncCitations (15 papers) → latexCompile → PDF with tables.

"Find code for hawthorn lipid profile analysis in ovariectomized models"

Research Agent → paperExtractUrls from Yoo et al. 2016 → paperFindGithubRepo → Code Discovery → githubRepoInspect (R script for Nrf2/HO-1 expression stats) → runPythonAnalysis adaptation.

Automated Workflows

Deep Research workflow conducts systematic review: searchPapers (hawthorn CVD, 250M+ OpenAlex) → citationGraph → readPaperContent on top 50 → GRADE + runPythonAnalysis for pooled ORs in heart failure. DeepScan applies 7-step CoVe to verify Holubarsch et al. (2017) benefit-risk claims with statistical checkpoints. Theorizer generates hypotheses on flavonoid mechanisms from Wu et al. (2020) atherosclerosis data.

Try Doxa for Hawthorn Herbal Medicine Clinical Efficacy Research

Frequently Asked Questions

What defines hawthorn clinical efficacy studies?

Studies focus on standardized Crataegus leaf-flower extracts in RCTs for NYHA II-III heart failure, hypertension, and dyslipidemia, measuring exercise capacity, blood pressure, and lipids (Wang et al., 2013; Koch and Malek, 2011).

What are main methods in hawthorn trials?

Randomized blinded trials like HERB CHF use 6-minute walk tests and adjunctive therapy with beta-blockers; meta-analyses pool NYHA data with fixed/random effects models (Zick et al., 2009; Holubarsch et al., 2017).

Which are key papers on hawthorn efficacy?

Wang et al. (2013, 119 citations) reviews CVD prevention; Zick et al. (2009, 59 citations) reports HERB CHF trial; Holubarsch et al. (2017, 52 citations) assesses WS 1442 benefit-risk.

What open problems exist?

Long-term safety with polypharmacy, standardization across extracts, and large RCTs for dyslipidemia subgroups remain unresolved (Suroowan and Mahomoodally, 2015; Cloud et al., 2019).